Application of eschar treatment tincture in preparation of medicine for preventing and treating long-term depression and cognitive impairment induced by burn infection

Abstract

The invention discloses application of eschar treatment tincture in preparation of a medicine for treating burn infection induced long-term depression and cognitive impairment, relates to the technical field of medicine application, and particularly provides any one of the following application of eschar treatment tincture: 1, application of eschar treatment tincture in preparation of a medicine for preventing and treating burn infection induced long-term depression, and 2, application of eschar treatment tincture in preparation of a medicine for preventing and treating burn infection induced long-term depression; 2, application in preparation of medicines for preventing and treating cognitive impairment induced by burn infection; 3, application in preparation of a medicine for reducing the concentration of serum corticosterone CORT; 4, application in preparation of drugs for reducing expression of mRNA of corticotropin-releasing hormone CRH; and 5, application in preparation of drugs for regulating the HPA axis function. The scabbing tincture has the beneficial effects that the novel application of the scabbing tincture in treating long-term depression and cognitive impairment induced by burn infection is provided, the wound healing of a burn patient can be improved, the learning and memory ability of the burn patient can be improved, depression related behaviors of the burn patient can be improved, and the scabbing tincture has a relatively good application prospect.

Description

Technical Field

[0001] The invention relates to the technical field of medicine, and in particular to application of scab-forming tincture in preparing medicine for preventing and treating long-term depression and cognitive impairment induced by burn infection. Background Art

[0002] Burns refer to tissue damage caused by heat, electric current, radiation or chemicals, with typical symptoms including skin redness, blisters, pain, etc. Since a large amount of exudate and necrotic tissue after burns provide an ideal environment for microbial proliferation, coupled with skin barrier damage and immune dysfunction, patients are very susceptible to wound infection. Wound infection not only delays wound healing, but in severe cases can also cause complications such as systemic inflammatory response, sepsis and multiple organ dysfunction syndrome, endangering the patient's life.

[0003] In recent years, burn treatment technology and anti-infection measures have been continuously developed, greatly improving the survival rate of burn patients. However, in the process of wound treatment and rescue of burn infection, the long-term neuropsychiatric and behavioral changes caused by it are often ignored. In addition to the pain caused by burns and infections, the local and systemic inflammatory reactions associated with burn infections can have a negative impact on patients' emotions and cognitive behaviors through various pathways, increasing their risk of depression and cognitive impairment. Animal experimental results show that bacterial lipopolysaccharide stimulation can not only lead to an increase in the concentration of inflammatory factors in rat serum, but also induce typical depressive-like behaviors such as decreased activity, increased despair behavior, and loss of pleasure, accompanied by learning and memory dysfunction. In-depth mechanism exploration results show that experimental animals stimulated by lipopolysaccharide have neuropathic changes such as damage to hippocampal neurons and synaptic plasticity, and activation of microglia.

[0004] In the treatment of burn and scald infection, many types of drugs are currently widely used in clinical practice, including sulfadiazine silver cream, moist burn ointment, mupirocin ointment, iodine tincture, etc. Sulfadiazine silver cream has excellent performance in the treatment of skin infections, burns, scalds, etc. with its antibacterial, bactericidal, and anti-inflammatory effects. It can quickly relieve symptoms and promote wound healing. However, its use must strictly follow the doctor's instructions to avoid excessive or long-term use to prevent the occurrence of adverse reactions. Moist burn ointment promotes wound healing and recovery by maintaining a moist environment at the scalded site, while preventing infection and reducing scar formation, but care should be taken to keep the wound clean and dry when using it. Mupirocin ointment, as an external antibiotic, is mainly used for skin infections caused by Gram-positive cocci. It has significant antibacterial, anti-inflammatory, and analgesic effects, but may have adverse reactions such as local burning and tingling. As a commonly used drug for burn wounds, iodine tincture has a long-lasting bactericidal effect, but has a weak effect on bacterial spores and fungal spores. However, these drugs all focus on the treatment of burn wounds themselves, and there are currently no reports on the effectiveness of these drugs in preventing and alleviating long-term depressive symptoms and cognitive impairment in burn infection patients. Therefore, it is difficult to meet the comprehensive treatment needs of patients.

[0005] As a traditional Chinese medicine preparation, scab-making tincture has shown unique advantages in the treatment of burn and scald infections. Its main ingredients include Chinese medicinal materials such as Phellodendron, Scutellaria, Catechu, and Borneol. Phellodendron is cold in nature, bitter in taste, and belongs to the kidney meridian, bladder meridian, and large intestine meridian. It has the effects of clearing heat and dampness, purging fire and detoxifying; Scutellaria is cold in nature and bitter in taste, and belongs to the lung, gallbladder, spleen, large intestine, and small intestine meridians. It has the effects of clearing heat and purging fire, purging dampness and detoxifying; Catechu is bitter, astringent, and slightly cold in nature, and belongs to the lung and heart meridians. It is a blood-activating and healing medicine; Borneol can not only clear heat and detoxify, but also relieve pain and promote tissue regeneration. It can be used externally for treatment after scalds and burns. It is pungent, bitter, and slightly cold in nature, and belongs to the heart, spleen, and lung meridians. However, there have been no reports on the use of scab-making tincture for the treatment of long-term depression, cognitive impairment, etc. Summary of the invention

[0006] The technical problem to be solved by the invention is how to provide a new medical application of the scab-making tincture.

[0007] The present invention solves the above technical problems through the following technical means:

[0008] The first aspect of the present invention proposes any application of scab-forming tincture in the following:

[0009] (1) Use in the preparation of drugs for preventing and treating long-term depression induced by burn infection;

[0010] (2) Use in the preparation of drugs for preventing and treating cognitive impairment induced by burn infection;

[0011] (3) Use in the preparation of drugs for reducing serum corticosterone CORT concentration;

[0012] (4) Use in the preparation of a drug for reducing the mRNA expression of corticotropin-releasing hormone (CRH);

[0013] (5) Application in the preparation of drugs for regulating HPA axis function.

[0014] Preferably, the ingredients of the scab-forming tincture include Phellodendron amurense, Scutellaria baicalensis, Catechu and Borneol.

[0015] Preferably, the mass ratio of Phellodendron chinense, Scutellaria baicalensis, Catechu and Borneol is 2:2:2:1.

[0016] Preferably, the scab-forming tincture is prepared by the following process: processing Phellodendron chinense, Scutellaria baicalensis and Catechu into coarse powders according to proportions, placing them in a covered container, adding ethanol to mix well, sealing and placing for a period of time, soaking in ethanol after moistening, preparing by percolation, collecting the percolation liquid, adding borneol to dissolve it, and then adding ethanol to stir well to obtain the tincture.

[0017] The second aspect of the present invention provides a product having any one or more of the following effects:

[0018] (1) Prevent and treat long-term depression induced by burn infection;

[0019] (2) Prevent and treat cognitive impairment induced by burn infection;

[0020] (3) Application of drugs that reduce serum corticosterone CORT concentration;

[0021] (4) reduce the mRNA expression of corticotropin-releasing hormone (CRH);

[0022] (5) Regulate HPA axis function;

[0023] The ingredients of the product include scab-forming tincture.

[0024] Preferably, the product is any one of food, medicine and health care product.

[0025] Preferably, the product is a medicine, and the medicine further comprises pharmaceutically acceptable excipients.

[0026] Preferably, the pharmaceutically acceptable excipient is selected from one or more of a diluent, an excipient, a filler, a binder, a wetting agent, a disintegrant, an absorption promoter, a surfactant, an adsorption carrier and a lubricant.

[0027] Preferably, the drug is prepared into a pharmaceutically acceptable dosage form.

[0028] Preferably, the dosage form is tablet, pill, paste, capsule, oral solution or granule.

[0029] The beneficial effects of the present invention are:

[0030] 1. The present invention proposes a new use of scab-forming tincture in the treatment of long-term depression and cognitive impairment induced by burn infection, which can not only improve the wound healing of burn patients, but also improve the learning and memory ability of burn patients and improve their depression-related behaviors, and has good application prospects.

[0031] 2. The present invention proposes that scab-forming tincture can improve long-term depressive-like behavior and cognitive impairment, and its mechanism is related to regulating inflammatory immune response and hypothalamus-pituitary-adrenal (HPA) axis function. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 The effect of the scab-forming tincture on the body weight of scalded rats in Example 1 of the present invention is shown in FIG.

[0033] Figure 2 The effect of the scab-forming tincture on the wound healing rate of scalded rats in Example 1 of the present invention is shown in FIG.

[0034] Figure 3 This is a general observation diagram of the scab-forming tincture on the wound surface of scalded rats in Example 1 of the present invention (n=3);

[0035] Figure 4 This is an observation diagram of pathological HE staining of the wound surface of scalded rats by the scab-forming tincture in Example 1 of the present invention (n=3);

[0036] Figure 5 Effect of the scab-forming tincture in Example 2 of the present invention on the blood routine test of scalded rats on the 3rd, 14th and 30th days

[0037] Figure 6 This is a graph showing the effect of the scab-forming tincture in Example 2 of the present invention on HE pathological staining of the spleen of scalded rats (n=3);

[0038] Figure 7 The scab-forming tincture in Example 2 of the present invention has an effect on the CD3 + Impact map of flow cytometry

[0039]

[0040] Figure 8 The scab-forming tincture in Example 2 of the present invention has an effect on the CD4 + / CD8 + Impact map of flow cytometry

[0041] Fig. 9 The effect of the scab-forming tincture in Example 3 of the present invention on the open field test of scalded rats

[0042] Fig.10 The effect of the scab-forming tincture in Example 3 of the present invention on the elevated plus maze test of scalded rats

[0043]

[0044] Fig.11 The effect of the scab-forming tincture in Example 3 of the present invention on the novel object recognition test and the forced swimming test in scalded rats is shown in FIG.

[0045] Fig.12 This is a graph showing the results of serum corticosterone CORT concentration detection in Example 4 of the present invention;

[0046] Fig.13 This is a graph showing the detection result of the mRNA expression level of corticotropin-releasing hormone CRH in Example 4 of the present invention;

[0047] exist Figures 1 to 13 middle:

[0048] *P<0.05, **P<0.01, ***P<0.01, comparison between the two groups indicated by the lines. DETAILED DESCRIPTION

[0049] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be clearly and completely described in combination with the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0050] Unless otherwise specified, the test materials and reagents used in the following examples can be obtained from commercial sources.

[0051] If no specific techniques or conditions are specified in the examples, they can be carried out according to the techniques or conditions described in the literature in the art or according to the product instructions.

[0052] In the following examples, the scab-making tincture is provided by the preparation room of the First Affiliated Hospital of Anhui Medical University, batch number 20231215, which is composed of the following raw materials in parts by weight: 100g of Phellodendron (coarse powder), 100g of Scutellaria baicalensis (coarse powder), 100g of catechu (coarse powder), 50g of borneol (fine powder), and 1000ml of ethanol (volume percentage 80%). The preparation steps are as follows: Phellodendron chinense, Scutellaria baicalensis, and catechu are processed into coarse powders and placed in a covered container, mixed with appropriate amount of ethanol, and sealed for 4 hours after wetting and then soaked in ethanol for 72h, prepared by percolation, collecting percolation liquid, adding borneol, dissolving, adding ethanol to the full amount, and stirring to obtain. Moist burn ointment is a product of Shantou Meibao Pharmaceutical Co., Ltd., and the approval number is National Medicine Standard Z20000004.

[0053] Embodiment 1:

[0054] This example provides the effect of scab-forming tincture in the treatment of burns and burn infection wounds, and studies the effect of scab-forming tincture on wound healing in high temperature-induced burn and burn infection model rats.

[0055] Forty-eight 8-week-old SD rats weighing 200-250 g were randomly divided into 8 groups of 6 rats each, namely:

[0056] Control group (C)

[0057] Burn model group (S)

[0058] Burn + Pseudomonas aeruginosa infection group (S+P)

[0059] After successful modeling, the scab-forming tincture treatment group:

[0060] burn + high-dose scab-forming tincture treatment group (S+H), burn + Pseudomonas aeruginosa infection + low-dose scab-forming tincture group (S+P+L), burn + Pseudomonas aeruginosa infection + high-dose scab-forming tincture treatment group (S+P+H);

[0061] At the same time, a positive control drug (MEBO) treatment group was set up:

[0062] Burn + MEBO treatment group (S+B), burn + Pseudomonas aeruginosa infection + MEBO treatment group (S+P+B).

[0063] High-dose scab-forming tincture refers to the dosage of 4 ml of the original scab-forming tincture per rat, and low-dose scab-forming tincture refers to the dosage of 4 ml of the original solution diluted with ethanol (volume percentage 80%) at a ratio of 1:1 per rat. The dosage of moist burn ointment used is to apply it evenly on the wound of each rat to a thickness of 0.8 mm.

[0064] After routine depilation of the rat back skin, a burn model was induced by contacting the middle back skin (20% body surface area) with a 100°C metal block for 12 seconds. The burn + Pseudomonas aeruginosa infection group was treated with Pseudomonas aeruginosa liquid (1.5×10 8 CFU / mL), 1 ml was applied to each rat. The control group rats were exposed to the same area of ​​skin at 37°C for 12 seconds with the same metal block. Each treatment group was smeared and medicated according to the above grouping 30 minutes after modeling, twice a day for 30 days. The rat weight and skin wound size were recorded daily. Figure 1-4 shown.

[0065] The body weight changes of rats in each group over 30 days were as follows Figure 1 As shown in the figure, the weight of rats in each group increased with time. However, compared with the control group, the rats in the burn model group (S) and the burn + Pseudomonas aeruginosa infection group (S+P) lost weight, and the weight loss in the burn infection group (S+P) was more significant. There was no statistical difference in the weight changes of rats in the scab-forming tincture and moist burn ointment treatment groups compared with the model group, but on the 30th day after scalding, the weight of the scab-forming tincture treatment group showed an upward trend compared with the model group. The dynamic changes of the wound healing rate of rats in each group are shown in the figure. Figure 2 , Figure 3 The results showed that the treatment of scab-forming tincture and moist burn ointment can promote the healing of scalded rats, especially the high-dose scab-forming tincture has a significant effect on the improvement of scald + Pseudomonas aeruginosa infected wounds and is better than the moist burn ointment treatment group. HE staining ( Figure 4 ) The results showed that after 12 seconds of contact with a 100℃ metal block, rat skin damage reached the dermis, and a large number of inflammatory cells infiltrated, which was consistent with deep II degree burns. After 30 days of treatment with scab-making tincture and moist burn ointment, collagen fibers, blood vessels and skin appendages were formed, which was consistent with the results of wound healing rate. Only after infection with Pseudomonas aeruginosa, the skin healing effect of the scab-making tincture treatment group was earlier than that of the moist burn ointment treatment group. The above results suggest that scab-making tincture treatment can improve burn wound damage, promote recovery and healing, especially when combined with Pseudomonas aeruginosa infection.

[0066] Embodiment 2:

[0067] This embodiment provides a scab-forming tincture that can treat burn infection while improving the inflammatory immune response disorder induced by the burn infection.

[0068] Blood samples were collected from rats in each group in Example 1 on the 3rd, 14th and 30th day after modeling to detect blood routine indicators such as white blood cell count, neutrophil ratio, lymphocyte ratio, etc. On the 30th day after modeling, the spleen of the rats was taken for HE staining to observe the structural integrity of the spleen capsule and red pulp, white pulp, germinal center, etc. and the number of spleen bodies; on the 30th day after modeling, the spleen tissue of the rats was taken for flow cytometry to detect the CD3 + 、CD4 + 、CD8 + Count, the result is Figure 7 and Figure 8 shown.

[0069] Blood routine data such as Figure 5 As shown in the figure, rats with 20% body surface area deep II degree burns had skin damage accompanied by inflammatory response activation-like hematological changes such as increased white blood cell count and increased neutrophil ratio, which were more significant in the group with Pseudomonas aeruginosa infection. On the 30th day after modeling, the white blood cell count and neutrophil ratio in the blood of rats in the burn + Pseudomonas aeruginosa infection model group were still significantly higher than those in the control group, and the lymphocyte ratio decreased, but there was improvement in the group treated with scab-forming tincture, and the effect of the moist burn ointment treatment group on simple burns without Pseudomonas aeruginosa infection was more significant.

[0070] HE staining results of spleen of rats after 30 days of modeling are as follows Figure 6 As shown in the figure, compared with the control group, the spleen capsule, red pulp, white pulp, germinal center and other structures of the burn and burn infected rats were intact, but the spleen corpuscles increased. + 、CD4 + / CD8 + The flow cytometry results are as follows Figure 7 , Figure 8 The results showed that compared with the control group, 30 days after modeling, the spleen CD3 + The number of CD4+ Tgp ... + / CD8 + The ratio increased, and recovered to near normal levels after treatment with different doses of scab-forming tincture or moist burn ointment, and there was no significant difference between the two treatment groups. The above results show that scab-forming tincture can improve inflammatory immune dysfunction in rats with 20% body surface area deep second-degree burns with or without Pseudomonas aeruginosa infection.

[0071] Embodiment 3:

[0072] This example provides the effect of scab-forming tincture on long-term depressive-like behavior and cognitive impairment induced by burn infection while treating burn infection.

[0073] The rats in each group in Example 1 were subjected to open field test, novel object recognition test, elevated plus maze test and forced swimming test 30 days after modeling to observe their neuropsychiatric behavioral changes. Among them, the open field test is a classic paradigm for studying the general sensory and motor abilities of animals, the novel object recognition test is used to study the cognitive function of rats, and the elevated plus maze test and forced swimming test are used to study the anxiety and depression-like performance of rats. Before all experiments, the rats were placed in the laboratory environment to adapt for at least half an hour, and the experimental area was cleaned and dried during the experiment to ensure that there was no odor.

[0074] The open field test apparatus is a black rectangular box with a size of 100cm×100cm×30cm. During the experiment, the rats were gently placed in a corner of the test box and their behaviors within 5 minutes were recorded, including defecation, standing upright, grooming, the time spent in the central and peripheral areas, the distance moved, the number of line crossings, etc. The new object experiment used the same box, and the experiment was divided into two parts: the adaptation period and the test period.

[0075] The first day of the experiment was the adaptation period: the rats were placed in the arena with their heads facing the wall of the box and allowed to freely explore for 10 min to familiarize themselves with the environment;

[0076] The second day is the testing period, which is divided into two stages:

[0077] Phase 1: Two identical objects were placed at one-third of the diagonal line of the bottom of the box, and the rats in each group in Example 1 were placed in the arena with their heads facing the wall of the box to freely explore for 10 min;

[0078] After 24 hours, the second stage began: one of the old objects was replaced with a new object of different color and shape, and its position was kept unchanged. The rats' exploration behavior of the new and old objects was recorded within 5 minutes, and the rats' preference index for the new object (the ratio of the time the rats explored the new object to the time they explored the new and old objects) was calculated and compared.

[0079] The elevated plus maze consists of two opposite open arms (without side walls) and two opposite closed arms (with side walls), forming a cross-shaped layout. The bottom of the maze is about 50 cm above the ground to simulate the high-altitude environment. During the experiment, the rats were allowed to explore freely for 5 minutes. The number of entries into the open arms and the length of stay were recorded.

[0080] The forced swimming test was conducted in a transparent cylindrical bucket with a diameter of 20 cm and a height of 40 cm. The water level during the experiment was appropriate so that the rats could not touch the bottom or climb to escape. The swimming time, struggling time and immobility time of the rats within 5 minutes were recorded during the experiment.

[0081] The behavioral results of rats in each group were as follows Figure 9-11 shown. Fig. 9 and Fig.10 The results showed that there was no statistical difference in the performance of rats in the open field test and elevated plus maze test, indicating that scald and scald + Pseudomonas aeruginosa infection had no significant effect on the general sensation and autonomous activity ability of rats.

[0082] like Fig.11 As shown in the results, compared with the control group, the new object priority index of rats in the burn + Pseudomonas aeruginosa infection group in the new object recognition experiment was significantly reduced, indicating a decline in learning and memory ability. High-dose scab-forming tincture treatment can improve the new object priority index of rats in the burn + Pseudomonas aeruginosa infection group in the new object recognition experiment, but the moist burn ointment treatment group cannot play a similar role. This suggests that high-dose scab-forming tincture treatment can task-specifically improve the learning and memory impairment of burn + infection rats.

[0083] The immobility time in the forced swimming test mainly reflects the desperate behavior of the experimental animals. Fig.11 As shown, compared with the control group, the immobility time of rats in the scald and scald + Pseudomonas aeruginosa infection groups in the forced swimming test was significantly prolonged, while the immobility time of rats in the high- and low-dose scab-forming tincture and moist burn ointment treatment groups was significantly shortened, suggesting their improvement effects on despair and depression behaviors.

[0084] The above results suggest that scab-forming tincture can be used to prevent and treat long-term learning and memory impairment and depressive-like behavior in rats induced by burn infection, and its protective effect on learning and memory ability is better than that of moist burn ointment.

[0085] Embodiment 4:

[0086] This example provides the effects of scab-forming tincture on serum corticosterone (CORT) concentration and hypothalamic corticotropin-releasing hormone (CRH) expression in the HPA axis (hypothalamus-pituitary-adrenal axis) of burned rats, reflecting its effects on the HPA axis function of burned infected rats.

[0087] Blood samples were collected from rats in each group of rats in Example 1 on the 3rd, 14th and 30th days after modeling, and serum corticosterone (CORT) concentration was detected by enzyme-linked immunosorbent assay (ELISA). On the 30th day after modeling, hypothalamic tissues of rats were taken for real-time fluorescence quantitative PCR to detect the mRNA expression level of CRH, and the primer sequences are shown in Table 1.

[0088] Table 1 Primer sequences for CRH and internal reference β-actin

[0089]

[0090] For specific results, see Figure 12 to Figure 13 .like Fig.12As shown in the figure, compared with the control group, the serum CORT concentration of rats in the scald and scald + Pseudomonas aeruginosa infection groups continued to increase after modeling, and was significantly reduced in the scab-forming tincture treatment group and the moist burn ointment treatment group. In addition, for the scald + Pseudomonas aeruginosa infection model, the serum CORT concentration of rats can be restored to a level close to that of the normal group after 30 days of high-dose scab-forming tincture treatment. Fig.13 As shown in the figure, compared with the control group, the mRNA expression of CRH in the hypothalamus of rats in the scald and scald + Pseudomonas aeruginosa infection groups increased significantly, while the high-dose scab-forming tincture treatment group returned to a near normal level, while there was no significant difference in the moist burn ointment treatment group. The above results suggest that the improvement of the neuropsychiatric behavior of rats with 20% body surface area deep second-degree burns with or without Pseudomonas aeruginosa infection by scab-forming tincture is related to its regulation of HPA axis function.

[0091] In summary, scab-making tincture can not only promote wound healing in scalded rats, but also improve their long-term depressive-like behavior and decreased learning and memory ability; its mechanism may be related to regulating inflammatory immune response and HPA function. Combined with the effects of scab-making tincture on wound recovery, inflammatory immune response, sensation, movement, emotion and learning and memory ability of rats with burn infection in this study, especially the effect on hypothalamic CRH mRNA expression, it is reasonable to believe that the external use of scab-making tincture can prevent and treat neurobehavioral abnormalities associated with burn infection through the dual effect experiment of peripheral and central regulation. More specific biological mechanisms and component analysis need further in-depth exploration.

[0092] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit the same. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that the technical solutions described in the aforementioned embodiments may still be modified, or some of the technical features may be replaced by equivalents. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. Any of the following uses of scab-forming tincture: (1) Use in the preparation of drugs for preventing and treating long-term depression induced by burn infection; (2) Use in the preparation of drugs for preventing and treating cognitive impairment induced by burn infection; (3) Use in the preparation of drugs for reducing serum corticosterone CORT concentration; (4) Use in the preparation of a drug for reducing the mRNA expression of corticotropin-releasing hormone (CRH); (5) Application in the preparation of drugs for regulating HPA axis function.

2. The use according to claim 1, characterized in that: The ingredients of the scab-forming tincture include Phellodendron chinense, Scutellaria baicalensis, catechu and borneol.

3. The use according to claim 2, characterized in that: The mass ratio of the Phellodendron chinense, Scutellaria baicalensis, Catechu and Borneol is 2:2:2:

1.

4. The use according to claim 3, characterized in that: The scab-making tincture is prepared by the following process: processing Phellodendron chinense, Scutellaria baicalensis and Catechu into coarse powders according to proportion respectively, placing them in a covered container, adding ethanol to mix well, sealing and placing for a period of time, soaking in ethanol after wetting, preparing by percolation method, collecting the percolation liquid, adding borneol to dissolve it, and then adding ethanol to stir well to obtain the scab-making tincture.

5. A product having any one or more of the following effects: (1) Prevent and treat long-term depression induced by burn infection; (2) Prevent and treat cognitive impairment induced by burn infection; (3) Application of drugs that reduce serum corticosterone CORT concentration; (4) reduce the mRNA expression of corticotropin-releasing hormone (CRH); (5) Regulate HPA axis function; The ingredients of the product include scab-forming tincture.

6. The product according to claim 5, characterized in that: The product is any one of food, medicine and health care product.

7. The product according to claim 6, characterized in that: The product is a medicine, which also includes pharmaceutically acceptable excipients.

8. The product according to claim 7, characterized in that: The pharmaceutically acceptable pharmaceutical excipient is selected from one or more of a diluent, an excipient, a filler, a binder, a wetting agent, a disintegrant, an absorption promoter, a surfactant, an adsorption carrier and a lubricant.

9. The product according to claim 7, characterized in that: The drug is prepared into a pharmaceutically acceptable dosage form.

10. The product according to claim 9, characterized in that: The dosage form is tablet, pill, paste, capsule, oral liquid or granule.

Images